University of Oxford PRINCIPLE Study Now Includes Ivermectin

University of Oxford PRINCIPLE Study Now Includes Ivermectin

Back in January 2021, TrialSite reported that the University of Oxford was “considering” ivermectin for its PRINCIPLE clinical trial or the “Platform Randomized Trial of Treatments in the Community for Epidemic and Pandemic Illnesses.” Backed by the UK government via the Department of Health and Social Care as well as Oxford Nuffield Department of Primary Care Health Sciences, the importance and stature of this study was, and is, promising. However, given the pervasive “regulatory capture” problem, TrialSite’s suggested that the generic drug triggered worldwide controversy and pressure, and for months, it wasn’t clear if the University of Oxford was moving forward or not with ivermectin. Now there’s confirmation in the popular press that the ivermectin study arm is in fact moving forward. Of course, one challenge is timing – much like in the U.S., where the National Institutes of Health (NIH) via its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, ACTIV-6 also included ivermectin recently – ivermectin proponents argue this occurred a year too late given the death toll of the pandemic. These proponents posit that there’s compelling evidence now that...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee